stockrowCuris, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024.
- Revenue
- −66.0%
- EPS
- +70.4%
- Free cash flow
- −20.4%
Quarter to June 2026, against a year earlier
Follow CRIS
Alert me
Curis, Inc. (CRIS) EV/Sales
As of 6 November 2026, Curis, Inc. (CRIS) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −5.2× (May 2022) to 597× (February 2015); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | 1,916.01% |
| FY2024 | 0.0× | (95.54%) |
| FY2023 | 1.1× | — |
| FY2022 | −2.6× | — |
| FY2021 | 30.2× | 41.41% |
| FY2020 | 21.3× | 116.86% |
| FY2019 | 9.8× | 201.11% |
| FY2018 | 3.3× | (64.88%) |
| FY2017 | 9.3× | (82.74%) |
| FY2016 | 53.9× | 41.02% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1.0× | (37.94%) |
| Sep 2025 | 1.6× | (12.60%) |
| Jun 2025 | 1.8× | — |
| Mar 2025 | −0.1× | — |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −71.4× |
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| EVGN Evogene Ltd. compare | −3.6× |
| LGVN Longeveron Inc. compare | −3.1× |
| CRIS Curis, Inc. | −0.3× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| ORGS Orgenesis Inc. compare | 16.9× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)